AstraZeneca at #ASH24 (Max Gelman for Endpoints News)
December 8, 2024 07:37 PM EST
R&D

As­traZeneca re­veals first clin­i­cal da­ta for bis­pe­cif­ic T cell en­gager from TeneoT­wo buy­out

Max Gelman

Senior Editor

SAN DIEGO — As­traZeneca is get­ting ready to step on the gas in the world of bis­pe­cif­ic T cell en­gagers.

The com­pa­ny pre­sent­ed some of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Vir’s ear­ly T cell en­gager da­ta of­fer first look at can­cer piv­ot, stock jumps

ARCH, F-Prime and Mubadala pump $200M in­to for­mer De­nali pro­grams

Up­dat­ed: Gala­pa­gos to split in­to two com­pa­nies, slash head­count as it eyes turn­around

Sana’s stock soars on new cell ther­a­py da­ta; UniQure’s $75M of­fer­ing

Ex­clu­sive: First-of-its-kind in­fant DNA ed­it leads to ap­par­ent cure in dis­ease that set back field 25 years ago

Every FDA drug ap­proval from 2024: Few­er nods, but long-await­ed treat­ments cross the fin­ish line

A service from the Financial Times